Objectives. To compare the incidence of metabolic alterations (hypercholesterolemia >200 mg/dl, hypertriglyceridemia >175 mg/dl and hyperglycemia >110 mg/dl) in patients (pts) with prostate cancer (PCa) treated with androgen deprivation therapy (ADT) with/without normalization of testosterone levels (NTL). Materials and methods. Retrospective analysis of 304 pts with PCa, treated with ADT and radiotherapy in our hospital from October 2001 to December 2009, to compare the incidence of metabolic

more »

... lterations in pts with/without NTL. 176 pts (58%) had normalization of testosterone levels with a median time of 10.4 months. Patients without NTL were significantly older, higher risk group and with increased median time of ADT. Median follow-up was 56 months (range 16-167). We examined the values of cholesterol, triglycerides and glucose in all the checkups during the follow up. Results. In each group 48% of the pts had a record of metabolic alterations (23% and 30% hypercholesterolemia, 16% and 9% hyperglycemia and 9% and 10% a combination of hypercholesterolemia and hyperglycemia or hypertriglyceridemia). 88% and 89% of pts with or without NTL during the follow up had metabolic alterations (28% hypercholesterolemia in both groups, 9.4% and 8.5% hyperglycemia, 7% and 8% hypertriglyceridemia and 21% a combination of hypercholesterolemia and hyperglycemia with or without hypertriglyceridemia) and in 82% the disorder was present in more than one checkup. Conclusions. Patients with PCa treated with ADT, with/without NTL had a similar prevalence of metabolic record alterations and incidence of metabolic disorder during the follow up. Hypercholesterolemia and hyperglycemia were the most frequent metabolic alterations found in these pts. http://dx.